Skip to main content
Download PDF
  • Correspondence
  • Open access
  • Published:

Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2023 ASH annual meeting

Experimental Hematology & Oncology volume 13, Article number: 17 (2024) Cite this article

Abstract

Patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) often exhibit limited responses to traditional chemotherapy, resulting in poor prognosis. The combination of venetoclax (VEN) with hypomethylating agents has been established as the standard treatment for elderly or medically unfit AML patients unable to undergo intensive chemotherapy. Despite this, the availability of novel VEN-based therapies specifically tailored for those with R/R AML remains scarce. Here, we provide a comprehensive overview of the latest data presented at the 65th American Society of Hematology Annual Meeting, shedding light on the progress and efficacy of VEN-based therapies for R/R AML.

To the editor,

Relapsed or refractory (R/R) acute myeloid leukemia (AML) poses a formidable challenge with a grim prognosis. Venetoclax (VEN), a BCL2 inhibitor, has exhibited remarkable anti-leukemic activity in combination with hypomethylating agents (HMA) or low-dose cytarabine (Ara-C) for newly diagnosed unfit AML patients [1]. However, the efficacy of VEN-based therapy in R/R AML remains less defined. This review provides an overview of the recent advances in VEN-based therapies for R/R AML presented at the 2023 American Society of Hematology (ASH) meeting.

VEN combined with chemotherapy drugs for R/R AML

VEN plus CPX-351, a liposomal fixed-ratio formulation containing Ara-C and daunorubicin, achieved a 45% overall response rate (ORR). After a median follow-up time of 20.7 months, the median overall survival (OS) and event-free survival (EFS) were 6.4 and 2.8 months, respectively. Among responders, the 2-year cumulative incidence of relapse and non-relapse mortality were 41% and 28%, respectively [2]. It produces encouraging response rates and is safe in R/R AML.

The clinical effectiveness of the VEN in combination with the CAG regimen (consisting of Ara-C, aclarubicin, and G-CSF) was assessed in patients diagnosed with R/R AML. The composite complete remission (CCR) was 78.4%, the rate of minimal residual disease (MRD) elimination in patients who achieved CCR was 44.8%, and the one-year OS was 78.4% [3]. It manifests that the combination is safe and active in patients with R/R AML.

The results of VEN plus high-dose Ara-C and mitoxantrone (HAM) in patients with R/R AML were updated. The mortality rates at 30 and 60 days were 2.6% and 5.2%, respectively. The complete remission (CR)/CR with incomplete count recovery (CRi) was 81.6%, and 21.9% of evaluable patients were MRD negative [4]. It confirms that VEN + HAM is a well-tolerated and very efficacious treatment option.

The initial efficacy of VEN and selinexor in combination with chemotherapy (fludarabine, Ara-C ± G-CSF) [FLA(G)] was assessed in pediatric, adolescent and young adult (AYA) patients with R/R AML. It demonstrated a CR/CRi rate of 41.7%, with 50% of the patients undergoing hematopoietic cell transplant following the completion of protocol therapy [5]. It shows that this combination is tolerable in AYA patients.

The investigation focused on studying the combination of VEN with liposomal mitoxantrone, homoharringtonine, and olverembatinib (MVHO), aiming to block multiple pathways in pediatric patients with R/R AML. After cycle one, the ORR was 94.4%, and the CR/CRi was 72.2%. The 8-month mean EFS was 60.1% and the OS was 100%. Throughout 26 cycles of MVHO treatment, there were no reported fatal infections or bleeding events [6].

In this series, VEN plus HAM seems to be effective and well-tolerated, while MVHO therapy may be a suitable treatment option for pediatric R/R AML, warranting further validation through larger clinical trials.

VEN combined with epigenetic drugs for R/R AML

VEN with ASTX727 (oral decitabine/cedazuridine) in R/R AML achieved a 50% ORR. After a median follow-up of 12.8 months, the median OS was 7.6 months, with a median duration of response (DOR) of 4.6 months [7]. This combination is effective and tolerable.

The VEN, chidamide plus azacytidine (VAC) combination has exhibited synergy with both low-intensity and intensive chemotherapy in preclinical studies and in patients with R/R AML. The updated results of the VAC combination showed an ORR of 68%. With a median follow-up of 6.7 months, the median OS was not reached [8]. It proves that VCA has encouraging efficacy in patients with R/R AML.

A multi-center study was conducted to evaluate whether the addition of VEN to the azacitidine plus homoharringtonine (VAH) regimen could improve the response in patients with R/R AML. Compared with VEN + azacitidine, the triplet of VAH significantly improved composite remission rate (CRc) rate (66.3% vs. 44.3%, P < 0.001) and prolonged OS (no reach vs. 14.3 months, P = 0.004) in R/R AML [9].

Similarly, VAH plus sorafenib achieved a high ORR of 82.4% in R/R AML with FLT3-ITD. At a median follow-up of 10.3 months, the median OS was 18.1 months and EFS was 13.2 months [10].

In this series, an entirely oral regimen consisting VEN and ASTX727 may be an effective and convenient treatment option, while ‘VAH ± sorafenib’ regimes show high activity and promise, necessitating exploration in larger population trials.

VEN combined with antibody or targeted drugs for R/R AML

VEN plus enasidenib, an oral selective IDH2 inhibitor, achieved a 70% ORR in IDH2-Mutated R/R AML. With a median follow-up of 17.1 months, the median OS was 9.4 months and the 2-year OS rate was 42%. Importantly, no cases of IDH inhibitor-associated differentiation syndrome were reported [11]. It shows that the combination is safe and well-tolerated in those patients.

The updated results of the combination of VEN and pegylated crisantaspase (PegC) showed an ORR of 47%, without serious asparaginase-related adverse events [12]. This combination is well-tolerated and can induce CR in some heavily R/R AML patients.

In conclusion, the 2023 ASH annual meeting showcased compelling efficacy and safety data for VEN-based therapies in R/R AML (refer to Tables 1 and 2), including MVHO, VAH ± sorafenib, VEN + enasidenib, etc. These findings underscore the feasibility of VEN-based treatments in managing R/R AML.

Table 1 VEN combined with chemotherapy drugs for R/R AML
Full size table
Table 2 VEN combined with epigenetic, antibody or targeted drugs for R/R AML
Full size table

Data availability

Not applicable.

Abbreviations

AE:

adverse events

AML:

acute myeloid leukemia

AZA:

azacitidine

CAG:

Ara-C, aclarubicin, and G-CSF

CCR:

composite complete remission

CR:

complete remission

CRc:

composite remission rate

CRi:

CR with incomplete count recovery

DOR:

duration of response

EFS:

event-free survival

FLA(G):

fludarabine, Ara-C ± G-CSF

HAM:

high-dose Ara-C and mitoxantrone

HHT:

Homoharringtonine

HMA:

hypomethylating agents

MRD:

minimal residual disease

ORR:

overall response rate

OS:

overall survival

PegC:

pegcrisantastase

R/R:

relapsed or refractory

VEN:

venetoclax

References

  1. Xie J, Bao X, Xue SL, Shen H, Cen J, Yao L, et al. Venetoclax with decitabine as frontline treatment in younger adults with newly diagnosed ELN adverse-risk AML. Blood. 2023;142(15):1323–7.

    Article  CAS  PubMed  Google Scholar 

  2. Bataller A, Bazinet A, Borthakur G, Short NJ, Jabbour E, Takahashi K, et al. CPX-351 with venetoclax in patients with relapsed/refractory acute myeloid leukemia: results of a phase ib study. Blood. 2023;142(Suppl 1):4259.

    Article  Google Scholar 

  3. Yu W, Wu Y, Chen Q, Zhu X, Pei X, Jia J, et al. Comparison of safety and efficacy between venetoclax combined with CAG (cytarabine, aclarubicin, G-CSF) regimen and CAG regimen alone in patients with relapsed or refractory acute myeloid leukemia. Blood. 2023;142(Suppl 1):1525.

    Article  Google Scholar 

  4. Ruhnke L, Schliemann C, Mikesch J, Stelljes M, Fransecky L, Steffen B, et al. Venetoclax plus high-dose cytarabine and mitoxantrone (HAM-Ven) as salvage treatment for relapsed/refractory AML: updated results of the phase-I/II SAL relax trial. Blood. 2023;142(Suppl 1):160.

    Article  Google Scholar 

  5. Zarnegar-Lumley S, Karol SE, Pounds S, Klco JM, Sulis ML, Kuo DJ, et al. Preliminary safety and efficacy of venetoclax and selinexor in combination with chemotherapy in pediatric and young adult patients with relapsed or refractory acute myeloid leukemia: selclax. Blood. 2023;142(Suppl 1):56.

    Article  Google Scholar 

  6. Hu W, Wang Z, Chen C, Shen S. Combination of liposomal mitoxantrone, venetoclax, homoharringtonine, and olverembatinib (HQP1351) (MVHO) in pediatric patients with refractory or relapsed acute myeloid leukemia (AML): case series. Blood. 2023;142(Suppl 1):2840.

    Article  Google Scholar 

  7. Bazinet A, Garcia-Manero G, Short NJ, Valero YA, Abuasab T, Islam MR, et al. A phase 2 study of the fully oral combination of ASTX727 (decitabine/cedazuridine) plus venetoclax for older and/or unfit patients with acute myeloid leukemia. Blood. 2023;142(Suppl 1):833.

    Article  Google Scholar 

  8. Zha J, Wang Y, Li Z, Lin Z, Cai Y, Gong T, et al. Update results of a phase II trial of venetoclax in combination with azacitidine and chidamide in relapsed/refractory acute myeloid leukemia. Blood. 2023;142(Suppl 1):4274.

    Article  Google Scholar 

  9. Yu G, Zhang Y, Jin H, Yin Z, Weng G, Yu S, et al. Homoharringtonine overcomes the negative impact of genetic patterns on venetoclax plus azacitidine regimen in relapsed/refractory acute myeloid leukemia: a multi-center, cohort study. Blood. 2023;142(Suppl 1):4262.

    Article  Google Scholar 

  10. Yu S, Liu Q, Zhang Y, Yu G, Wang Y, Shao R, et al. Sorafenib plus triplet therapy with venetoclax, azacitibine and homoharringtonine for refractory/relapsed acute myeloid leukemia with FLT3-ITD: a multicentre, phase 2 study. Blood. 2023;142(Suppl 1):1530.

    Article  Google Scholar 

  11. Richard-Carpentier G, Gupta G, Cameron C, Cathelin S, Bankar A, Davidson MB, et al. Final results of the phase Ib/II study evaluating enasidenib in combination with venetoclax in patients with IDH2-Mutated relapsed/refractory myeloid malignancies. Blood. 2023;142(Suppl 1):159.

    Article  Google Scholar 

  12. Liu Y, Bollino D, Bah OM, Strovel ET, Zarrabi J, Philip S, et al. Overcoming venetoclax (Ven) resistance through glutamine (gln) depletion: final analysis of the phase 1 trial of Ven and pegcrisantaspase (PegC) combination in relapsed and refractory (R/R) acute myeloid leukemia (AML). Blood. 2023;142(Suppl 1):60.

    Article  Google Scholar 

Download references

Acknowledgements

We are thankful to many specialists in the field whose seminal works are not cited due to space constraints. We would like to express my gratitude to all those who helped us during the writing of this review.

Funding

This work was supported by grants from the Natural Science Foundation of China (grant no. 81400107), and Zhejiang Medical and Health Science and Technology Project (2022RC154).

Author information

Author notes

  1. Xubo Gong and Xin He contributed equally to this work.

Authors and Affiliations

  1. Department of Clinical Laboratory, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, Zheijang, P.R. China

    Xubo Gong, Lin Wang, Weiwei Liu, Huiying Xu, Lan Jin, Xiang Li & Zhihua Tao

  2. Department of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, Hematologic Malignancies and Stem Cell Transplantation Institute, Beckman Research Institute, City of Hope Medical Center, 1500 E Duarte Road, Duarte, CA, 91010, USA

    Xin He & Bin Zhang

  3. Department of Hematology, The Second Affiliated Hospital, Zhejiang University School of Medicine, 88 Jiefang Road, Hangzhou, 310009, China

    Teng Yu & Wenbin Qian

Authors
  1. Xubo Gong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xin He
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lin Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Teng Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Weiwei Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Huiying Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Lan Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Xiang Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Bin Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Zhihua Tao
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Wenbin Qian
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

X.G., X.H., B.Z., Z.T., and W.Q. were the principal investigators. X.G. drafted the manuscript. H.X., W.L., and T.Y. prepared the tables. All authors participated in the process of drafting and revising the manuscript. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Bin Zhang, Zhihua Tao or Wenbin Qian.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gong, X., He, X., Wang, L. et al. Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2023 ASH annual meeting. Exp Hematol Oncol 13, 17 (2024). https://doi.org/10.1186/s40164-024-00486-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s40164-024-00486-7

Keywords

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us